Table 2.
Baseline characteristics of the study participants (after PSM)
| Variables | Total (n = 42) | Matched cohort | ||
|---|---|---|---|---|
| cTACE (n = 21) | cTACE+MWA (n = 21) | p | ||
| Age, mean ± SD | 59.0 ± 9.4 | 60.7 ± 9.9 | 57.3 ± 8.8 | 0.249 |
| Sex, n (%) | 1 | |||
| Female | 3 (7.1) | 2 (9.5) | 1 (4.8) | |
| Male | 39 (92.9) | 19 (90.5) | 20 (95.2) | |
| HBV, n (%) | 1 | |||
| No | 5 (11.9) | 3 (14.3) | 2 (9.5) | |
| Yes | 37 (88.1) | 18 (85.7) | 19 (90.5) | |
| HCV, n (%) | 1 | |||
| No | 39 (92.9) | 19 (90.5) | 20 (95.2) | |
| Yes | 3 (7.1) | 2 (9.5) | 1 (4.8) | |
| AFP, n (%) | 1 | |||
| <200ng/ml | 27 (64.3) | 14 (66.7) | 13 (61.9) | |
| ≥200ng/ml | 15 (35.7) | 7 (33.3) | 8 (38.1) | |
| CP, n (%) | 1 | |||
| A | 39 (92.9) | 19 (90.5) | 20 (95.2) | |
| B | 3 (7.1) | 2 (9.5) | 1 (4.8) | |
| Tumor size, median (IQR) | 3.4 (3.1, 4.1) | 3.4 (3.1, 4.1) | 3.5 (3.2, 4.1) | 0.612 |
| Portal hypertension, n (%) | 1 | |||
| No | 19 (45.2) | 9 (42.9) | 10 (47.6) | |
| Yes | 23 (54.8) | 12 (57.1) | 11 (52.4) | |
| PLT (×109/L), median | 91.0 (67.2, 138.5) | 88.0 (67.0, 137.0) | 98.0 (70.0, 139.0) | 0.772 |
| TBIL (μmol/L), mean ± SD | 13.3 ± 5.7 | 13.9 ± 6.4 | 12.7 ± 5.0 | 0.512 |
| CRE (μmol/L), mean ± SD | 66.6 ± 8.9 | 65.1 ± 8.6 | 68.0 ± 9.2 | 0.296 |
| INR, mean ± SD | 1.1 ± 0.1 | 1.1 ± 0.1 | 1.1 ± 0.1 | 0.653 |
Notes: data presented are mean ± SD, median (Q1–Q3), and N (%)
Abbreviations: HBV hepatic B virus, HCV hepatic C virus, AFP alpha-fetoprotein, CP Child-Pugh Classification, PLT platelet, TBIL total bilirubin, CRE creatinine, INR prothrombin time-international normalized ratio